No Data
Minsheng Securities: The results of medical insurance negotiations are now available, key products successfully included in the medical insurance catalog.
With the support of policies such as health insurance, the level of new drug research and development in China is continuously improving, the industrial scale is constantly expanding, and the number of new drugs under development in the country has jumped to the second place globally, accelerating the transition to high-quality innovation.
Jiangsu Hengrui Medicine Sees Inclusion of 12 Drugs in National Medical Insurance Catalog; Shares Up 3%
Jiangsu Hengrui Pharmaceuticals (600276.SH): The company's pharmaceuticals are included in the national medical insurance catalog.
On November 28th, Hengrui Pharmaceuticals (600276.SH) announced that, through medical insurance negotiations, Fumag Taijili Ding injection, Otokangzuo capsule, Henggelijing Metformin sustained-release tablets (Ⅰ)(Ⅱ) were first included in the national medical insurance catalog; Fluzopali capsules were added to the national medical insurance catalog under the new indication through the simple renewal rule; Injection of Carirelizumab was successfully renewed and new indications were added to the national medical insurance catalog through the simple renewal rule; Hydroethanesulfonic acid darzile tablets, rivaroxaban tablets, pregabalin sustained-release tablets were successfully renewed through the simple renewal rule and retained in the national medical insurance catalog; Fuamino Henggeliejing tablets renewal.
SPDB International HK Starts Jiangsu Hengrui Pharmaceuticals at Buy With 61 Yuan Price Target
Hengrui Medicine's Unit Gets Regulatory Nod to Trial Atopic Dermatitis Drug; Shares Up 3%
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years AgoNo Data
No Data
